Search results for "Thrombolysi"

showing 10 items of 120 documents

Thrombolysis for massive pulmonary embolism in pregnancy: a case report

2011

Mortality from pulmonary embolism (PE) in pregnancy might be related to challenges in targeting the right population for prevention. Such targeting could help ensure that the correct diagnosis is suspected and adequately investigated, and allow the initiation of the timely and best possible treatment of this disease. In the literature to date only 18 case reports of thrombolysis in pregnant women with PE have been reported, and showed beneficial effects for both mother and fetus in terms of mortality and complications with acceptable bleeding risks. We present here the case of a pregnant patient with massive PE who underwent successful thrombolysis. A 26-year-old pregnant (at 24 weeks) woma…

medicine.medical_specialtyFetusPregnancyeducation.field_of_studymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentPopulationCase ReportThrombolysisChest painmedicine.diseasePulmonary embolismmedicine.anatomical_structureInternal medicineEmergency MedicinemedicineCardiologyInterventricular septummedicine.symptombusinesseducationPelvic examinationInternational Journal of Emergency Medicine
researchProduct

Endovascular embolectomy of the superior mesenteric artery using the Rotarex® system for the treatment of acute mesenteric ischemia.

2016

medicine.medical_specialtyMechanical Thrombolysismedicine.medical_treatmentEmbolectomy030204 cardiovascular system & hematologyEmbolectomy03 medical and health sciences0302 clinical medicineAcute mesenteric ischemiaMechanical ThrombolysisMesenteric Artery SuperiorInternal medicinemedicine.arteryInternal MedicinemedicineHumansSuperior mesenteric arteryAgedbusiness.industryEndovascular ProceduresEndovascular embolectomymedicine.diseaseMesenteric ischemia030220 oncology & carcinogenesisMesenteric IschemiaCardiologyFemalebusinessPolskie Archiwum Medycyny Wewnetrznej
researchProduct

Coronary thrombolysis with tissue-type plasminogen activator (t-PA)

1985

Coronary thrombolysis is presently under intensive investigation as a treatment for acute myocardial infarction for two main reasons. Firstly it is now well established that acute myocardial infarction is often associated with thrombotic occlusion of an atherosclerotic coronary artery [1]. Secondly it has been shown that administration of thrombolytic agents can reopen an occluded coronary artery in the majority of patients [2, 3] and that reperfusion of ischemic myocardial tissue is generally well tolerated. Coronary thrombolysis is however not a goal in itself but is employed to prevent necrosis and dysfunction of jeopardized myocardial cells. There is ample evidence in animals that the i…

medicine.medical_specialtyNecrosisbusiness.industryCoronary reperfusionmedicine.diseasemedicine.anatomical_structureCoronary thrombosisInternal medicineCoronary thrombolysismedicineCardiologyThrombolytic AgentMyocardial infarctionmedicine.symptombusinessPlasminogen activatorArtery
researchProduct

Use of bivalirudin for heparin-induced thrombocytopaenia after thrombolysis in massive pulmonary embolism: a case report

2009

A 68-year-old man was referred to the emergency department 6 h after onset of sudden acute dyspnoea. Immediate ECG showed sinus tachycardia with the typical S1-Q3-T3 pattern and incomplete right bundle branch block. The echocardiogram showed the presence of mobile thrombus in the right atrium, a distended right ventricle with free wall hypokinesia and displacement of the interventricular septum towards the left ventricle. Lung spiral computed tomography (CT) showed bilateral pulmonary involvement and confirmed the picture of a thrombotic system in the right atrium and caval vein. Thrombolytic treatment with recombinant tissue plasminogen activator (rt-PA) and heparin (alteplase 10 mg bolus,…

medicine.medical_specialtySettore MED/09 - Medicina Internamedicine.medical_treatmentCase ReportInternal medicinebivalirudin Heparin-induced thrombocytopaenia Pulmonary embolism ThrombolysismedicineBivalirudinHeparin-induced thrombocytopaeniaInterventricular septumcardiovascular diseasesThrombusLungbusiness.industryPulmonary embolismThrombolysismedicine.diseaseThrombolysisSpiral computed tomographyPulmonary embolismmedicine.anatomical_structureVentricleCardiologycardiovascular systemEmergency MedicinebusinessBivalirudinmedicine.drugInternational Journal of Emergency Medicine
researchProduct

Low-frequency ultrasound induces nonenzymatic thrombolysis in vitro.

2002

To evaluate whether ultrasound, applied over a distance of several centimeters and in the absence of thrombolytic agents, may have a thrombolytic effect on blood clots.Low-frequency (20 kHz) continuous wave ultrasound at different intensity levels (0.15-1.2 W/cm2) and exposure times (5, 10, and 20 minutes) was assessed for its potential to induce thrombolysis of fresh human blood clots. The ultrasound effect was also studied in combination with recombinant tissue-type plasminogen activator-mediated thrombolysis. Experiments were carried out in a flow model in degassed sodium phosphate buffer at 37 degrees C at a distance of 3 cm from the ultrasonic probe to the blood clots. Regardless of ul…

medicine.medical_specialtyTime FactorsRadiological and Ultrasound Technologybusiness.industrymedicine.medical_treatmentUltrasonic TherapyUltrasoundHemodynamicsThrombolysismedicine.diseaseThrombosisRecombinant ProteinsSurgeryThrombolytic drugTissue Plasminogen ActivatorFibrinolysismedicineThrombolytic AgentHumansRadiology Nuclear Medicine and imagingThrombolytic TherapybusinessNuclear medicinePlasminogen activatorJournal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
researchProduct

A new thrombectomy catheter device (AngioJet) for the disruption of thrombi: An in vitro study

1999

In this study we examined a new thrombectomy catheter device. Different kinds of in vitro generated thrombi and cadaver thrombi were disrupted in test tubes. The mean disruption rate (and disruption time for 1 g of thrombus) was 225 +/- 65 mg/sec (5 +/- 2 sec) for whole-blood, 117 +/- 60 mg/sec (12 +/- 9 sec) for fibrin, 41 +/- 18 mg/sec (30 +/- 18 sec) for mixed, 70 +/- 42 mg/sec (17 +/- 5 sec) for unorganized, 45 +/- 8 mg/sec (22 +/- 4 sec) for partly, and 5 +/- 1 mg/sec (216 +/- 29 sec) for completely organized cadaver thrombi (P0.05). More than 99% of fragmented particles of whole-blood thrombi were 0-12 microm in diameter. The particle size of fibrin, mixed, and cadaver thrombi was sim…

medicine.medical_specialtyTime Factorsmedicine.medical_treatmentIn Vitro TechniquesFibrinCatheterizationCadavermedicineHumansRadiology Nuclear Medicine and imagingParticle SizeThrombusThrombectomybiologybusiness.industryCatheter deviceThrombosisEquipment DesignGeneral MedicineThrombolysismedicine.diseaseThrombosisPulmonary embolismSurgerymedicine.anatomical_structureEmbolismbiology.proteinPulmonary EmbolismCardiology and Cardiovascular MedicineNuclear medicinebusinessArteryCatheterization and Cardiovascular Interventions
researchProduct

Nonroutine Use of Intra-Aortic Balloon Pump in Cardiogenic Shock Complicating Myocardial Infarction With Successful and Unsuccessful Primary Percutan…

2018

Abstract Objectives The authors sought to compare outcomes of patients with myocardial infarction and cardiogenic shock (CS) treated with percutaneous coronary intervention (PCI) with or without intra-aortic balloon pump (IABP) support according to final epicardial flow in the infarct-related artery. Background A routine use of IABP is contraindicated in patients with myocardial infarction and CS. There are no data regarding the subpopulation of patients who may benefit from such support besides patients with mechanical complications of myocardial infarction. Methods Prospective nationwide registry data of patients with myocardial infarction and CS treated with PCI between 2003 and 2014 wer…

medicine.medical_specialtyTime Factorsmedicine.medical_treatmentShock Cardiogenicprimary PCI030204 cardiovascular system & hematology03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineRisk FactorsInternal medicinemedicineHumansProspective StudiesRegistriescardiovascular diseases030212 general & internal medicineMyocardial infarctionIABPNon-ST Elevated Myocardial InfarctionIntra-aortic balloon pumpIntra-Aortic Balloon Pumpingbusiness.industryCardiogenic shockHazard ratiocardiogenic shockPercutaneous coronary interventionRecovery of FunctionThrombolysismedicine.diseaseTreatment Outcomesurgical procedures operativemyocardial infarctionConventional PCICardiologyST Elevation Myocardial InfarctionPolandCardiology and Cardiovascular MedicinebusinessTIMIJACC-Cardiovascular Interventions
researchProduct

Primary angioplasty versus intravenous thrombolysis in acute myocardial infarction: can we define subgroups of patients benefiting most from primary …

2001

Abstract OBJECTIVES We sought to determine the effectiveness of primary angioplasty compared with thrombolysis in clinical practice. BACKGROUND In clinical practice, primary angioplasty for the treatment of acute myocardial infarction (AMI) has not yet been proven more effective than intravenous thrombolysis, nor have subgroups of patients been identified who would perhaps benefit from primary angioplasty. METHODS The pooled data of two AMI registries—the Maximal Individual TheRapy in Acute myocardial infarction (MITRA) study and the Myocardial Infarction Registry (MIR)—were analyzed. A total of 9,906 lytic-eligible patients with AMI, with a pre-hospital delay of ≤12 h, were treated with ei…

medicine.medical_specialtyUnivariate analysisbusiness.industrymedicine.medical_treatmentAbsolute risk reductionThrombolysisOdds ratiomedicine.diseaseConfidence intervalInternal medicineConcomitantAngioplastyCardiologyMedicineMyocardial infarctionbusinessCardiology and Cardiovascular MedicineJournal of the American College of Cardiology
researchProduct

Defining right ventricular dysfunction by the use of echocardiography in normotensive patients with pulmonary embolism

2020

Although the prognostic value of various echocardiographic parameters of right ventricular dysfunction (RVD) was reported in normotensive patients with acute pulmonary embolism (PE), there is no generally accepted definition of RVD.The aim of the study was to compare echocardiographic parameters for the prediction of an adverse 30‑day outcome and create an optimal definition of RVD.                                     Patients and methods: Echocardiographic parameters including the right ventricular to left ventricular diameter ratio (RV to LV ratio) and tricuspid annular plane systolic excursion (TAPSE) to predict PE‑related mortality, hemodynamic collapse, or rescue thrombolysis within th…

medicine.medical_specialtyVentricular Dysfunction Rightmedicine.medical_treatmentHemodynamicsBlood Pressure030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInternal medicineInternal MedicineHumansMedicineProspective Studies030212 general & internal medicineReceiver operating characteristicbusiness.industryArea under the curveThrombolysismedicine.diseaseRight ventricular dysfunction3. Good healthPulmonary embolismBlood pressureIncreased riskEchocardiographyCardiologyPulmonary EmbolismbusinessPolish Archives of Internal Medicine
researchProduct

New frontiers in anticoagulation: non vitamin-K oral anticoagulants in stroke prevention

2016

ABSTRACTIntroduction: Non vitamin-K oral anticoagulants (NOACs) are direct and specific inhibitors of the coagulation factors IIa (dabigatran) and Xa (apixaban, rivaroxaban, edoxaban) which share many pharmacokinetic properties. However, indications are lacking regarding the use of NOACs during thrombolysis, surgery and bleeding events.Areas covered: In this paper, the authors retrospectively analyzed the relevant literature on the NOACs using the PubMed and Google Scholar databases.Expert commentary: Although warfarin is effective in cardioembolic stroke prevention, easier handling and more favorable risk-benefit profile often render NOACs a more preferable therapy choice for neurologists.…

medicine.medical_specialtyVitamin KPyridonesaspirinmedicine.medical_treatmentAdministration Oral030204 cardiovascular system & hematologyDabigatranAnticoagulation03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEdoxabanmedicineHumansatrial fibrillationPharmacology (medical)030212 general & internal medicineIntensive care medicineRivaroxabanAspirinbusiness.industryGeneral Neurosciencenon vitamin-K oral anticoagulantWarfarinAnticoagulantsreverse therapyAtrial fibrillationThrombolysismedicine.diseasemeasure of monitoringStrokewarfarinchemistryAnesthesiaPyrazolesApixabanstroke preventionNeurology (clinical)businessmedicine.drugExpert Review of Neurotherapeutics
researchProduct